Browse News
Filter News
Found 683 articles
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Diagnostic Testing Market Size to Reach USD 449.78 Billion by 2033
4/16/2024
According to Nova One Advisor, the global diagnostic testing market is valued at USD 211.27 billion in 2023
-
U.S. Compounding Pharmacies Market Size, Share, CAGR, Report 2024 to 2033
4/15/2024
According to Vision Research Reports, the U.S. compounding pharmacies market size was estimated at USD 5.79 billion in 2023 and it is expected to increase around USD 10.39 billion by 2033 with a CAGR of 6.02% from 2024 to 2033.
-
Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening
4/4/2024
Grifols announced that its new Procleix ArboPlex Assay has obtained the CE mark under the In Vitro Diagnostic Regulation, the first for an automated nucleic acid test specifically validated for screening blood donors to detect four major arboviruses: chikungunya, dengue, West Nile and Zika viruses.
-
Olympus Corporation of the Americas' Julien Sauvagnargues Steps into CEO Role
3/27/2024
Olympus announced the appointment of Julien Sauvagnargues to the role of President and Chief Executive Officer, Olympus Corporation of the Americas, reporting to Olympus Chief Strategy Officer, Gabriela Kaynor, effective April 1, 2024.
-
Diagnostic Testing Market Size to Worth Around USD 284.38 Billion by 2033
3/20/2024
According to Vision Research Reports, the global diagnostic testing market size was estimated at USD 210.58 billion in 2023 and is expected to be worth around USD 284.38 billion by 2033 with a CAGR of 3.05% from 2024 to 2033.
-
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
3/5/2024
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and full year ended December 31, 2023.
-
Grifols announces positive topline phase 3 fibrinogen clinical trial results
2/14/2024
Grifols announced that Biotest’s positive topline results from AdFIrst, its phase 3 clinical trial of its fibrinogen concentrate, BT524, advance this potential treatment for acquired fibrinogen deficiency, an underserved growth market.
-
Rigel Pharmaceuticals Provides Business Update - Jan 08, 2024
1/8/2024
Rigel Pharmaceuticals, Inc. provided a business update including preliminary total revenue for the fourth quarter of 2023, ongoing activity from the commercial portfolio, including TAVALISSE® tablets and REZLIDHIA® capsules, and upcoming catalysts for 2024.
-
Cell Therapy Raw Materials Market Size, Share, Trends Report 2023 to 2032
12/19/2023
According to Vision Research Reports, the global cell therapy raw materials market size was valued at USD 3.49 billion in 2022 and it is predicted to surpass around USD 31.28 billion by 2032 with a CAGR of 24.52% from 2023 to 2032. The cell therapy raw materials market in the United States was accounted for USD 1.3 billion in 2022.
-
GigaGen Receives FDA Clearance of IND to Begin Phase 1 Trial of Oncology Drug Candidate, GIGA-564, in Solid Tumors
12/12/2023
GigaGen Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase 1 trial to evaluate the company’s oncology candidate, GIGA-564, for the treatment of solid tumors.
-
Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer
11/27/2023
Ocuphire Pharma, Inc. today announced the appointment of Joseph (Joe) K. Schachle, M.B.A., into the newly created role of Chief Operating Officer, effective today.
-
Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency
11/15/2023
Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS) today announced that it has completed Cohort 1 of its Phase 1/2 study (NCT04722887) evaluating Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% (Alpha-1 15%), a subcutaneous (SC) alpha1 antitrypsin (AAT) treatment being compared to Liquid Alpha1-Proteinase Inhibitor (Human) intravenous (IV).
-
Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update
11/7/2023
Rigel Pharmaceuticals, Inc. reported financial results for the third quarter ended September 30, 2023, including sales of TAVALISSE® tablets for the treatment of adults with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment and sales of REZLIDHIA® capsules for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 mutation as detected by an FDA-approved test.
-
GigaGen Presents IND-Enabling Data and Phase 1 Trial Strategy for its Novel Anti-CTLA-4 Oncology Drug Candidate, GIGA-564, at SITC 2023
11/6/2023
GigaGen Inc. presented investigational new drug (IND)-enabling data and the clinical trial design for its first-in-human Phase 1 study evaluating the company’s oncology candidate, GIGA-564, at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
-
While the trial was designed to test safety and not efficacy, patients treated with Araclon Biotech’s experimental ABvac40 vaccine saw a 38% drop in disease progression compared to placebo.
-
Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s Vaccine at CTAD
10/24/2023
Araclon Biotech, a Grifols Group company dedicated to the research and development of therapies and diagnostic methods applied to neurodegenerative diseases, today announced encouraging final results from its Phase 2 trial (NCT03461276) of ABvac40, an active vaccine against the Aβ40 peptide, for the treatment of patients with early-stage Alzheimer's disease (AD).
-
AIS Healthcare’s Advanced Infusion Care Announces Joint Study with Grifols to Continue Improving Patient Care
10/23/2023
Advanced Infusion Care, a division of AIS Healthcare, announced an agreement to conduct a joint study with Grifols, a leading global provider of essential plasma-derived and transfusion medicines, to observe the effects of subcutaneous immunoglobulin products on individuals living with primary immune deficiencies.
-
GigaGen Granted Expansion of Contract with US Department of Defense to Develop Synthetic Human Antibody Treatments for Botulinum Neurotoxins
10/19/2023
GigaGen Inc. a subsidiary of Grifols, announced the company has been granted an expansion of its contract with the U.S. Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense to develop synthetic human antibody treatments for botulinum neurotoxins.
-
Ashvattha Therapeutics Announces Appointment of Dr. Sakura Minami as Vice President of Translational Medicine and Nonclinical Development and Sarah Thayer as Head of Clinical Operations
10/9/2023
Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced the appointment of Sakura Minami, Ph.D., as Vice President of Translational Medicine and Nonclinical Development and Sarah Thayer as Head of Clinical Operations.